Immunovaccine Inc. Appoints Acting CFO, Keith Abriel

Immunovaccine Inc. Appoints Acting CFO, Keith Abriel
HALIFAX, NOVA SCOTIA--(Marketwire - 06/09/10) - Immunovaccine Inc., a vaccine development company, announced today that it has appointed Keith Abriel, C.A., as acting Chief Financial Officer, with immediate effect. Mr. Abriel will fulfill the role of acting CFO until the search is complete and a permanent appointment is made.

Immunovaccine Inc. (TSX-V:IMV - News) is a clinical stage vaccine development company focused on the commercialization of its patented DepoVaxTM vaccine delivery technology and product candidates. The company continues to strengthen its vaccine pipeline through licensing and strategic partnerships to develop therapeutic cancer and infectious disease vaccines. www.imvaccine.com.

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts: Immunovaccine Inc. Mr. Brian Lowe Vice President (902) 492-1819 [email protected] Immunovaccine Inc. Jennifer Ayotte Director Communications (902) 492-1819 [email protected] www.immunovaccine.com / www.imvaccine.com

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.